Faculty Collaboration Database

Mechanisms of thrombogenesis in polycythemia vera. Blood Rev 2015 Jul;29(4):215-21

Date

01/13/2015

Pubmed ID

25577686

Pubmed Central ID

PMC4466074

DOI

10.1016/j.blre.2014.12.002

Scopus ID

2-s2.0-84937164094 (requires institutional sign-in at Scopus site)   51 Citations

Abstract

Thrombotic and cardiovascular events are among the leading causes of death for patients with polycythemia vera (PV), and thrombosis history is a key criterion for patient risk stratification and treatment strategy. Little is known, however, about mechanisms of thrombogenesis in patients with PV. This report provides an overview of thrombogenesis pathophysiology in patients with PV and elucidates the roles of conventional and nonconventional thrombotic risk factors. In addition to several conventional risk factors for thrombosis, clinical data have implicated increased hematocrit and red blood cell adhesiveness, activated platelets, leukocytosis, and elevated JAK2(V617F) allele burden in patients with PV. Furthermore, PV-related inflammation may exacerbate thrombogenesis through varied mechanisms, including endothelial damage, inhibition of natural anticoagulant pathways, and secretion of procoagulant factors. These findings suggest a direct link between myeloproliferation and thrombogenesis in PV, which is likely to provide new opportunities for targeted antithrombotic interventions aimed at decreasing PV-related morbidity and mortality.

Author List

Kroll MH, Michaelis LC, Verstovsek S

Author

Laura Michaelis MD Chief, Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Humans
Polycythemia Vera
Risk Factors
Thrombosis